Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-2301 in Healthy Infants
NCT02140047Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Apr 2014
- Primary completion
- Jan 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of MT-2301 in Haemophilus influenzae type b infection (Hib) (3 arms), sponsored by Mitsubishi Tanabe Pharma. Primary endpoint: Antibody Prevalence Rate Against Anti-PRP With 1 μg/mL or Higher. Started Apr 2014; status: completed.
02
Drugs
MT-2301
03
Conditions
Haemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT02140047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02140047.